| Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing cell therapies to patients, particularly in solid tumors. Co.'s proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables Co. to identify cancer targets, find and genetically engineer T-cell receptors, and produce therapeutic candidates for administration to patients. Co. has three SPEAR T-cells in clinical trials, ADP-A2M10 (MAGE-A10), ADP-A2M4 (MAGE-A4) and ADP-A2AFP (AFP). A fourth SPEAR T-cell, the NY-ESO SPEAR T-cell is Co.'s collaboration with GlaxoSmithKline. We show 1 historical shares outstanding datapoints in our ADAP shares outstanding history coverage, used to compute ADAP market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ADAP market cap history over the course of time is important for investors
interested in comparing ADAP's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ADAP versus a peer is one thing; comparing
ADAP market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ADAP can fluctuate over the course of history.
With this page we aim to empower investors researching ADAP by allowing them to research the ADAP market cap history.